News | June 14, 2021
Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Subscribe To Our Newsletter & Stay Updated
